Quantcast

Latest CD133 Stories

2013-02-08 23:03:54

Stem cells taken from ALS patients may have the same capacity to develop into mature neuron-like cells as those collected from healthy donors, according to a new study released this month in STEM CELLS Translational Medicine. These findings could open doors to a possible new treatment option while also reducing the chance for rejection and other side effects often seen when someone other than the patient is the cell donor. Durham, NC (PRWEB) February 08, 2013 Stem cells taken from ALS...

2010-04-08 09:10:37

A nutritional supplement could stimulate the production of stem cells integral for repairing the body. Research published in BioMed Central's open access Journal of Translational Medicine suggests that a commercially-available supplement can increase the blood circulation of hematopoietic stem cells, which can give rise to all blood cells, and endothelial progenitor cells, which repair damage to blood vessels. Thomas E. Ichim from Medistem Incorporated, USA worked with a team of 13...

2010-02-03 22:39:03

Researchers at the Pontifícia Universidade Cat³lica do Paraná and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence. HUCB-derived EPCs could be...

2009-12-07 03:38:00

TAIPEI, Taiwan, Dec. 7 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009. The clinical data of Phase 1 study will be presented. In this randomized, double-blind, placebo-controlled, sequential ascending single intravenous dose study,...

2009-10-29 10:05:00

BERGISCH GLADBACH, Germany, October 29 /PRNewswire/ -- Miltenyi Biotec announces the treatment of the first patient in a phase III clinical trial termed PERFECT. The trial aims at determining whether intramyocardial injection of autologous CD133+ bone marrow stem cells improves heart function in addition to coronary artery bypass grafting (CABG) in patients with chronic ischemic heart disease and reduced pumping function. PERFECT is a randomized, prospective, double-blind,...

2008-10-10 09:00:52

ImmunoCellular Therapeutics, a biotechnology company, has filed a provisional US patent application relating to its vaccine technology targeting cancer stem cells. The vaccine technology is exclusively licensed from Cedars-Sinai Medical Center. The patent claims are broad and include compositions of peptides for cancer immunotherapy as well as methods for inducing immune responses against tumor antigens in cancer patients. The vaccine being developed by ImmunoCellular Therapeutics (IMUC)...

2008-07-10 09:01:29

ImmunoCellular Therapeutics has exclusively licensed from Cedars-Sinai Medical Center, certain novel peptides which can stimulate the immune system to target cancer stem cells in gliomas, a cancer originating in the brain or spine. According to the company, these peptides were specifically designed to elicit a T cell response targeting CD133 positive cancer stem cells that have been identified in a number of cancer types, including gliomas, colon cancer and pancreatic cancer. Manish...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related